Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Linical CoTSE:2183 +0.98%41 Debt-to-Equity is 0.57 as of Mar. 2026, which is 10% above its 10-year median of 0.52. GuruFocus rates TSE:2183 with a GF Score™ of 41/100 and a GF Value™ of 円331.75 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 958 Biotechnology companies, Linical Co ranks worse than 78.18% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Linical Co's Debt-to-Equity or its related term are showing as below:
TSE:2183'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.18 Med: 0.52 Max: 0.9
Current: 0.57
During the past 13 years, the highest Debt-to-Equity Ratio of Linical Co was 0.90. The lowest was 0.18. And the median was 0.52.
TSE:2183's Debt-to-Equity is ranked worse than 78.18% of 958
companies
in the Biotechnology industry
Industry Median: 0.16
vs TSE:2183: 0.57
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Linical Co Debt-to-Equity Related Terms
Linical Co Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Linical Co's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2183 vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Linical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Linical Co Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Linical Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Linical Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Linical Co (TSE:2183) has a Debt-to-Equity of 0.57 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Linical Co and its competitors. This is 10% above median its historical median of 0.52. Over the past decade, Linical Co's Debt-to-Equity has ranged from 0.18 to 0.90. According to the industry distribution chart, Linical Co ranks #749 out of 958 companies in the Biotechnology industry, placing it in the top 78.2%.
Is Linical Co's Debt-to-Equity too high?
Linical Co's current Debt-to-Equity of 0.57 is 10% above median its 10-year median of 0.52. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 0.90. The Biotechnology industry median Debt-to-Equity is 0.16. Linical Co's value of 0.57 is 256.3% above this industry median. Based on the distribution chart, Linical Co ranks #749 out of 958 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Linical Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Linical Co's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Linical Co ranks #749 out of 958 companies for Debt-to-Equity. This places Linical Co in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Linical Co's value of 0.57 is 256.3% above this benchmark. Historically, Linical Co's own Debt-to-Equity has ranged from 0.18 to 0.90 over the past decade. While the company's 10-year median is 0.52 vs. the industry median of 0.16, Linical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Linical Co's current Debt-to-Equity of 0.57 is 256.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Linical Co and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Linical Co's current Debt-to-Equity is 0.57, which is 10% above median its own 10-year median of 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Linical Co stock overvalued right now?
Based on GuruFocus' analysis, Linical Co (TSE:2183) is currently considered Possible Value Trap. The stock's GF Value™ is 円331.75, compared to a current price of 円207.00 — trading 37.6% below its estimated fair value. The current Debt-to-Equity is 0.57, which is 10% above median its 10-year median of 0.52 and 256.3% above the Biotechnology industry median of 0.16. Linical Co's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Linical Co (TSE:2183), the current Debt-to-Equity is 0.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Linical Co (TSE:2183) Overvalued in 2026?
Based on GuruFocus' analysis, Linical Co stock appears to be undervalued.
The current stock price of 円207.00 is trading 37.6% below its estimated GF Value™ of 円331.75.
GuruFocus considers Linical Co to be Possible Value Trap.
Key valuation signals for TSE:2183:
Debt-to-Equity: 0.57 (10% above median its 10-year median of 0.52)
GF Value™: 円331.75 vs. price of 円207.00 (37.6% below fair value)
Industry Position: 256.3% above the Biotechnology median (#749 of 958)
No single metric tells the full story. See the TSE:2183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2183 has been successfully added to your 
